Meeting
2013 ASCO Annual Meeting
Comprehensive pharmacogenetic profiling of advanced colorectal cancer.
Authors
Ayman Madi
Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom
Ayman Madi , David Fisher , Tim Maughan , James Colley , Angela M. Meade , Julie Maynard , Vikki Humpreys , Harpreet Wasan , Richard A. Adams , Shelley Idziaszczyk , Rebecca Harris , Laura L. Nichols , Richard S. Kaplan , Jeremy Cheadle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3509)
DOI
10.1200/jco.2013.31.15_suppl.3509
Abstract #
3509
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
First Author: Haeseong Park
Poster
2020 Gastrointestinal Cancers Symposium
Prospective DPYD testing and dose adjustment in colorectal cancer patients prior to fluoropyrimidine-based chemotherapy: Experience in a regional cancer center.
First Author: Janet Shirley Graham